Kiniksa Pharma
Kiniksa Pharmaceuticals International, plc develops IL‑1‑targeted therapies for unmet cardiovascular and inflammatory diseases, with Phase III ARCALYST for pericarditis and Phase IIb Vixarelimab for prurigo nodularis, positioning it for growth in niche markets.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 315
- HQ: London
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.